DE3889974T2 - Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten. - Google Patents

Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten.

Info

Publication number
DE3889974T2
DE3889974T2 DE3889974T DE3889974T DE3889974T2 DE 3889974 T2 DE3889974 T2 DE 3889974T2 DE 3889974 T DE3889974 T DE 3889974T DE 3889974 T DE3889974 T DE 3889974T DE 3889974 T2 DE3889974 T2 DE 3889974T2
Authority
DE
Germany
Prior art keywords
treatment agents
agents containing
cerebrovascular diseases
pyrazole derivatives
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3889974T
Other languages
English (en)
Other versions
DE3889974D1 (de
Inventor
Hiroyuki Yamashita
Makoto Odate
Hajime Iizuka
Hiroshi Kawazura
Yoshio Shiga
Hiroshi Namekawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Chemicals Inc
Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc
Application granted granted Critical
Publication of DE3889974D1 publication Critical patent/DE3889974D1/de
Publication of DE3889974T2 publication Critical patent/DE3889974T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE3889974T 1987-06-17 1988-06-16 Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten. Expired - Fee Related DE3889974T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14891987 1987-06-17

Publications (2)

Publication Number Publication Date
DE3889974D1 DE3889974D1 (de) 1994-07-14
DE3889974T2 true DE3889974T2 (de) 1994-09-15

Family

ID=15463593

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3889974T Expired - Fee Related DE3889974T2 (de) 1987-06-17 1988-06-16 Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten.

Country Status (7)

Country Link
US (2) US4839376A (de)
EP (1) EP0295695B1 (de)
KR (1) KR900004413B1 (de)
CN (1) CN1014245B (de)
CA (1) CA1311760C (de)
DE (1) DE3889974T2 (de)
HU (2) HU199825B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895947A (en) * 1987-12-17 1990-01-23 Mitsui Toatsu Chemicals, Inc. Process for producing 1-acyl-2-pyrazoline derivative
US5089622A (en) * 1988-12-12 1992-02-18 Mitsui Toatsu Chemicals Incorporated (-)-2-pyrazoline compounds and therapeutic agent for cerebrovascular disorders containing the same as effective ingredient
US5155126A (en) * 1990-03-20 1992-10-13 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with pyrazole, pyrrole and triazole angiotensin-II receptor antagonists
US5493024A (en) * 1991-04-11 1996-02-20 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insectioides
US5250532A (en) * 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
US5250561A (en) * 1991-08-08 1993-10-05 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors
US5338856A (en) * 1992-08-17 1994-08-16 Dowelanco 3,4-N,trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
WO2007008529A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
CN104030983A (zh) * 2014-03-21 2014-09-10 上海大学 含氟三苯基吡唑衍生物及其制备方法
TWI730959B (zh) * 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
TW201831464A (zh) * 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
CN114524828A (zh) * 2022-02-22 2022-05-24 深圳市儿童医院 一种用于治疗神经重症的噻唑衍生物及其应用
CN114524827A (zh) * 2022-02-22 2022-05-24 深圳市儿童医院 一种用于治疗神经重症的吡唑衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7408047A (de) * 1973-06-21 1974-12-24
US4250185A (en) * 1980-03-10 1981-02-10 Stauffer Chemical Company 1-(3,5-Dichlorobenzoyl)-3-phenylpyrazolines and their use as mildewicides
US4677210A (en) * 1985-06-19 1987-06-30 Rorer Pharmaceutical Corporation 1-arylalkoxy- and 1-arylalkylthioaryl-2-pyrazolines as anti-inflammatory or anti-allergic agents
JPH0730031B2 (ja) * 1986-04-02 1995-04-05 日産化学工業株式会社 ２―ピラゾリン―５―オン類の製造法
EP0268354A3 (de) * 1986-10-07 1988-06-15 Imperial Chemical Industries Plc Substituierte Pyrazoline

Also Published As

Publication number Publication date
EP0295695B1 (de) 1994-06-08
CN88103735A (zh) 1988-12-28
KR890000428A (ko) 1989-03-14
CN1014245B (zh) 1991-10-09
HU202106B (en) 1991-02-28
HUT47267A (en) 1989-02-28
EP0295695A2 (de) 1988-12-21
DE3889974D1 (de) 1994-07-14
HU896190D0 (en) 1990-02-28
EP0295695A3 (en) 1990-06-06
HU199825B (en) 1990-03-28
US4839376A (en) 1989-06-13
US4990529A (en) 1991-02-05
CA1311760C (en) 1992-12-22
KR900004413B1 (ko) 1990-06-25

Similar Documents

Publication Publication Date Title
DE3887353D1 (de) Behandlungsverfahren für magen-darm-krankheiten.
DE3775805D1 (de) Arzneimittel zur behandlung periodontaler erkrankungen.
ATA242288A (de) Dosierungsform für die behandlung kardiovaskulärer erkrankungen
DE3854540D1 (de) Behandlungsapparat und Verfahren.
DE69002057T2 (de) Reaktor für die behandlung von flüssigem kakao und seinen derivaten.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3882775T2 (de) Zusammensetzung zur Behandlung von parodontaler Krankheit.
DE3889974D1 (de) Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten.
DE3854326T2 (de) Aufbereitungstechnik für vollblutmuster.
DE3850433T2 (de) Allergiebehandlung und Zusammensetzung dafür.
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE3687692D1 (de) Geschlechtshormone zur behandlung von immun-mangel-krankheiten.
DE68909465D1 (de) Behandlung von pferdeviehbestand.
DE3871010D1 (de) Behandlung von unfruchtbarkeit.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
DK360884D0 (da) Farmaceutiske og veterinaere midler til behandling af iskaemiskehjertelidelser
DE9314149U1 (de) Therapeutisches Gerät für die Behandlung von Krankheitssymtomen
NO880292L (no) Fremgangsmaate for behandling av humle.
DE68907933T2 (de) Therapeutisches Mittel für Thrombocytopenia.
DK373688A (da) Behandlingsmetode
MA21254A1 (fr) Agent tannant
FI871605A0 (fi) Anordning foer skaerning av koett.
DE3883878D1 (de) Behandlungsapparat und Verfahren.
NO884635D0 (no) Fremgangsmaate for behandling av most.
DE3852245T2 (de) Isoprenderivate und diese enthaltende Anti-Ulcus-Mittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: KERN, R., DIPL.-ING., PAT.-ANW., 80686 MUENCHEN

8327 Change in the person/name/address of the patent owner

Owner name: MITSUI CHEMICALS, INC., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee